Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
12.37
+1.08 (9.57%)
At close: Nov 9, 2026, 4:00 PM EST
12.42
+0.05 (0.40%)
Pre-market: Nov 10, 2026, 7:01 AM EST
Ginkgo Bioworks Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 130.75 | 170.16 | 227.04 | 251.46 | 477.71 | 313.84 | |
Revenue Growth | -18.30% | -25.06% | -9.71% | -47.36% | 52.22% | 309.40% |
Cost of Revenue | 39.5 | 46.97 | 44.55 | 54.01 | 204.22 | 129.69 |
Gross Profit | 91.25 | 123.18 | 182.5 | 197.45 | 273.49 | 184.15 |
Selling, General & Admin | 173.03 | 187.52 | 237.15 | 350.66 | 1,417 | 862.95 |
Research & Development | 187.2 | 243.77 | 424.06 | 580.62 | 1,053 | 1,150 |
Operating Expenses | 360.23 | 431.3 | 661.21 | 931.28 | 2,470 | 2,013 |
Operating Income | -268.98 | -308.11 | -478.72 | -733.83 | -2,196 | -1,828 |
Interest Expense | - | - | -0.09 | -0.09 | -0.11 | -2.37 |
Interest & Investment Income | 14.6 | 22.62 | 38.61 | 57.22 | 20.26 | 0.84 |
Earnings From Equity Investments | -6.68 | - | - | -2.64 | -43.76 | -77.28 |
Other Non Operating Income (Expenses) | -2.97 | -4.53 | 9.57 | 14.31 | 132.6 | 56.88 |
EBT Excluding Unusual Items | -264.04 | -290.02 | -430.63 | -665.04 | -2,087 | -1,850 |
Merger & Restructuring Charges | -2.65 | -11.4 | -24.17 | -96.21 | -14.2 | - |
Impairment of Goodwill | - | - | -47.86 | - | - | - |
Gain (Loss) on Sale of Investments | -15.69 | -16.41 | -28.83 | -54.83 | -53.34 | -11.54 |
Gain (Loss) on Sale of Assets | - | - | -7.01 | -42.5 | 31.89 | - |
Asset Writedown | - | - | -5.8 | -25.19 | - | - |
Other Unusual Items | 4.23 | 4.23 | -3.21 | -9.17 | 1.26 | 23.83 |
Pretax Income | -278.14 | -313.6 | -547.51 | -892.94 | -2,121 | -1,838 |
Income Tax Expense | -0.87 | -0.84 | -0.48 | -0.07 | -15.03 | -1.48 |
Earnings From Continuing Operations | -277.27 | -312.76 | -547.03 | -892.87 | -2,106 | -1,837 |
Minority Interest in Earnings | - | - | - | - | 1.44 | 6.6 |
Net Income | -251.03 | -312.76 | -547.03 | -892.87 | -2,105 | -1,830 |
Net Income to Common | -251.03 | -312.76 | -547.03 | -892.87 | -2,105 | -1,830 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 61 | 55 | 52 | 49 | 42 | 34 |
Shares Outstanding (Diluted) | 61 | 55 | 52 | 49 | 42 | 34 |
Shares Change | 11.06% | 6.87% | 6.76% | 15.75% | 23.48% | 6.71% |
EPS (Basic) | -4.14 | -5.64 | -10.54 | -18.37 | -50.15 | -53.83 |
EPS (Diluted) | -4.14 | -5.64 | -10.54 | -18.37 | -50.20 | -55.53 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -173.54 | -178.72 | -382.13 | -336.3 | -304.47 | -310.34 |
Free Cash Flow Per Share | -2.86 | -3.22 | -7.36 | -6.92 | -7.25 | -9.13 |
Gross Margin | 69.79% | 72.39% | 80.38% | 78.52% | 57.25% | 58.68% |
Operating Margin | -205.72% | -181.08% | -210.85% | -291.84% | -459.70% | -582.62% |
Profit Margin | -191.99% | -183.81% | -240.94% | -355.08% | -440.63% | -583.12% |
Free Cash Flow Margin | -132.73% | -105.04% | -168.31% | -133.74% | -63.74% | -98.89% |
EBITDA | -235.23 | -267.82 | -433.7 | -679.03 | -2,153 | -1,799 |
EBITDA Margin | -179.91% | -157.40% | -191.02% | -270.04% | - | - |
D&A For EBITDA | 33.75 | 40.29 | 45.02 | 54.81 | 42.55 | 29.08 |
EBIT | -268.98 | -308.11 | -478.72 | -733.83 | -2,196 | -1,828 |
EBIT Margin | -205.72% | -181.08% | -210.85% | -291.84% | - | - |
Revenue as Reported | 170.16 | 170.16 | 227.04 | 251.46 | 477.71 | 313.84 |